Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, MS, Nicola Long, Anupriya Agarwal, PhD, Cristina E. Tognon, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 878.

https://doi.org/10.1182/blood-2019-126020

Published: 2019

Journal Articles

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, MS, Nicola Long, Jessica Leonard, MD, Bill H. Chang, MD PhD, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 3950.

https://doi.org/10.1182/blood-2019-131288

Published: 2019

Journal Articles

CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells

David K. Edwards, V, Kevin Watanabe-Smith, Angela Rofelty, Alisa Damnernsawad, Ted Laderas, Adam Lamble, Evan F. Lind, Andy Kaempf, Motomi Mori, Mara Rosenberg, Amanda d’Almeida, Nicola Long, Anupriya Agarwal, David Tyler Sweeney, Marc Loriaux, Shannon K. McWeeney, Jeffrey W. Tyner

Blood (2019) 133 (6): 588–599.

https://doi.org/10.1182/blood-2018-03-838946

Published: 2019

Includes: Supplemental data

Journal Articles

Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, Cristina E. Tognon, PhD, Motomi Mori, PhD, Max J. Gordon, MD, Jeffrey W. Tyner, PhD, Alexey V Danilov, MD PhD, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 214.

https://doi.org/10.1182/blood-2018-99-117468

Published: 2018

Journal Articles

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

Anna Reister Schultz, BS, Thomas Jacob, Christopher A. Eide, Samantha L Savage, Motomi Mori, PhD, Jeffrey W. Tyner, PhD, Cristina E. Tognon, PhD, Tania Q. Vu, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2018-99-115387

Published: 2018

Journal Articles

Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells

Stephen E Kurtz, PhD, Christopher A. Eide, Narain P. Dubey, Andy Kaempf, Shannon K. McWeeney, PhD, Cristina E. Tognon, PhD, Motomi Mori, PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Anupriya Agarwal, PhD

Blood (2018) 132 (Supplement 1): 2726.

https://doi.org/10.1182/blood-2018-99-117537

Published: 2018

Journal Articles

Proportion of Patients with FLT3 Positive AML Required to Enroll on Clinical Trials to Satisfy the Recruitment Needs of FLT3 Inhibitor Trials: Are We Running out of Patients?

Taylor Bucy, BA, John Zoscak, MS, Motomi Mori, PhD, Vinayak Prasad, MD, Uma Borate, MD

Blood (2018) 132 (Supplement 1): 713.

https://doi.org/10.1182/blood-2018-99-120142

Published: 2018

Journal Articles

Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, Samantha L Savage, Anna M. Reister Schultz, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Motomi Mori, PhD, Elie Traer, MD PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2017) 130 (Supplement 1): 2068.

https://doi.org/10.1182/blood.V130.Suppl_1.2068.2068

Published: 2017

Journal Articles

Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, Andrew Park, Angela Rofelty, Beth Wilmot, PhD, Daniel Bottomly, Shannon K. McWeeney, PhD, Cristina E. Tognon, PhD, Motomi Mori, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2017) 130 (Supplement 1): 1422.

https://doi.org/10.1182/blood.V130.Suppl_1.1422.1422

Published: 2017

Journal Articles

A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies

Stephen E Spurgeon, MD, Rachel Cook, MD MS, Elie Traer, MD, Uma Borate, MD, Richard T. Maziarz, MD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Tara Macey, PhD, Kristen Werth, Brian Junio, Cristina E. Tognon, Motomi Mori, PhD, Marc Loriaux, MD PhD

Blood (2016) 128 (22): 4051.

https://doi.org/10.1182/blood.V128.22.4051.4051

Published: 2016

Journal Articles

Identification of Effective Combinations of Targeted Drugs for Hematologic Malignancies

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, Vishesh Khanna, BS, Samantha L. Savage, Angela Rofelty, Isabel English, Hibery Ho, Motomi Mori, PhD, Elie Traer, MD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2016) 128 (22): 836.

https://doi.org/10.1182/blood.V128.22.836.836

Published: 2016

Journal Articles

Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma

Stephen Spurgeon, MD, Kamal Sharma, DO, David F. Claxton, MD, Christopher Ehmann, MD, Sara Shimko, BS, August Stewart, Samir Parekh, MD, Violetta V. Leshchenko, PhD, Yiyi Chen, PhD, Motomi Mori, Jeffrey J. Pu, MD PhD, Elliot Epner, MD PhD

Blood (2014) 124 (21): 1714.

https://doi.org/10.1182/blood.V124.21.1714.1714

Published: 2014

Journal Articles

In Vitro Drug Sensitivity as a Predicitive Tool of Early Clinical Response in Childhood Acute Lymphoblastic Leukemia.

Faith C. Galderisi, DO, Linda C. Stork, MD, Ju Li, MD, Motomi Mori, PhD, Solange Mongoue-Tchokote, James Huang, MD

Blood (2007) 110 (11): 4232.

https://doi.org/10.1182/blood.V110.11.4232.4232

Published: 2007

Journal Articles

Comparative Functional Genomic Analysis of Myelodysplasia (MDS) in Fanconi Anemia (FA).

Grover C. Bagby, MD, Shannon McWeeney, PhD, Jane Yates, Byung Park, PhD, R. Keaney Rathbun, Daniela Pilonetto, PhD, Richard Harris, MD, John Wagner, MD, Christina Harrington, PhD, Motomi Mori, PhD, Ricardo Pasquini, MD, D. Wade Clapp, MD

Blood (2006) 108 (11): 2636.

https://doi.org/10.1182/blood.V108.11.2636.2636

Published: 2006

Journal Articles

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML

Richard D. Press, Zac Love, Ashlie A. Tronnes, Rui Yang, Thuan Tran, Solange Mongoue-Tchokote, Motomi Mori, Michael J. Mauro, Michael W. Deininger, Brian J. Druker

Blood (2006) 107 (11): 4250–4256.

https://doi.org/10.1182/blood-2005-11-4406

Published: 2006

Journal Articles

Clonal Evolution of Fanconi Anemia (FA) Stem Cells Results from Clonal Adaptation and Clonal Selection. A Report from the International Fanconi Anemia Transcriptome Consortium.

Grover Bagby, MD, Jane Yates, Shannon McWeeney, PhD, Byung Park, MS, Keaney Rathbun, Daniela Pilonetto, PhD, Richard Harris, MD, John Wagner, MD, Gerard Pals, PhD, See Yan Lau, MS, Christina Harrington, PhD, Motomi Mori, PhD, Ricardo Pasquini, MD

Blood (2004) 104 (11): 3416.

https://doi.org/10.1182/blood.V104.11.3416.3416

Published: 2004

Journal Articles

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate

Michael E. O'Dwyer, Michael J. Mauro, Carolyn Blasdel, Melanie Farnsworth, Gwen Kurilik, Yi-Ching Hsieh, Motomi Mori, Brian J. Druker

Blood (2004) 103 (2): 451–455.

https://doi.org/10.1182/blood-2003-02-0371

Published: 2004

Journal Articles

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML

Michael E. O'Dwyer, Michael J. Mauro, Gwen Kurilik, Motomi Mori, Suzanne Balleisen, Susan Olson, Ellen Magenis, Renaud Capdeville, Brian J. Druker

Blood (2002) 100 (5): 1628–1633.

https://doi.org/10.1182/blood-2002-03-0777

Published: 2002

NARROW

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells

Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells

Proportion of Patients with FLT3 Positive AML Required to Enroll on Clinical Trials to Satisfy the Recruitment Needs of FLT3 Inhibitor Trials: Are We Running out of Patients?

Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia

Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations

A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies

Identification of Effective Combinations of Targeted Drugs for Hematologic Malignancies

Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma

In Vitro Drug Sensitivity as a Predicitive Tool of Early Clinical Response in Childhood Acute Lymphoblastic Leukemia.

Comparative Functional Genomic Analysis of Myelodysplasia (MDS) in Fanconi Anemia (FA).

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML

Clonal Evolution of Fanconi Anemia (FA) Stem Cells Results from Clonal Adaptation and Clonal Selection. A Report from the International Fanconi Anemia Transcriptome Consortium.

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only